Tirzepatide
GRABS-0
Eli Lilly · Phase 2/3 · Active, not recruiting · Enrollment 30
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Tirzepatide Group | Obesity or overweight | n/r | 24 | n/r | n/r |
| Control - Standard of care Post-Gastric Bypass Surgery | Obesity or overweight | n/r | 24 | n/r | n/r |